Natalia Smith-Cortinez

Dr. Natalia Smith-Cortinez

Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Cell Reports
Verified
Journal Article
Open access
CCCésar Cárdenas
César Cárdenas
MMMarioly Müller
Marioly Müller
AMAndrew McNeal
Andrew McNeal
ALAlenka Lovy
Alenka Lovy
FJFabian Jaňa
Fabian Jaňa
JFJ. Kevin Foskett
J. Kevin Foskett

11 November 2020 in Cells
Verified
Journal Article
Open access
PDF file
Natalia Smith-CortinezNatalia Smith-Cortinez
Natalia Smith-Cortinez
KEKaren van Eunen
Karen van Eunen
JHJanette Heegsma
Janette Heegsma
SSSandra Alejandra Serna-Salas
Sandra Alejandra Serna-Salas
SSSvenja Sydor
Svenja Sydor
KFKlaas Nico Faber
Klaas Nico Faber
Upon liver injury, hepatic stellate cells (HSCs) transdifferentiate to migratory, proliferative and extracellular matrix-producing myofibroblasts (e.g., activated HSCs; aHSCs) causing liver fibrosis. HSC activation is associated with increased glycolysis and glutaminolysis. Here, we compared the contribution of glycolysis, glutaminolysis and mitochondrial oxidative phosphorylation (OXPHOS) in rat and human HSC activation. Basal levels of glycolysis (extracellular acidification rate ~3-fold higher) and particularly mitochondrial respiration (oxygen consumption rate ~5-fold higher) were significantly increased in rat aHSCs, when compared to quiescent rat HSC. This was accompanied by extensive mitochondrial fusion in rat and human aHSCs, which occurred without increasing mitochondrial DNA content and electron transport chain (ETC) components. Inhibition of glycolysis (by 2-deoxy-D-glucose) and glutaminolysis (by CB-839) did not inhibit rat aHSC proliferation, but did reduce Acta2 (encoding α-SMA) expression slightly. In contrast, inhibiting mitochondrial OXPHOS (by rotenone) significantly suppressed rat aHSC proliferation, as well as Col1a1 and Acta2 expression. Other than that observed for rat aHSCs, human aHSC proliferation and expression of fibrosis markers were significantly suppressed by inhibiting either glycolysis, glutaminolysis or mitochondrial OXPHOS (by metformin). Activation of HSCs is marked by simultaneous induction of glycolysis and mitochondrial metabolism, extending the possibilities to suppress hepatic fibrogenesis by interfering with HSC metabolism.

24 November 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Natalia Smith-CortinezNatalia Smith-Cortinez
Natalia Smith-Cortinez
RFRaphael R. Fagundes
Raphael R. Fagundes
VGValentina Gomez
Valentina Gomez
DKDefu Kong
Defu Kong
DWDirk R. de Waart
Dirk R. de Waart
KFKlaas Nico Faber
Klaas Nico Faber
Liver fibrosis is characterized by the accumulation of extracellular matrix proteins, mainly composed of collagen. Hepatic stellate cells (HSCs) mediate liver fibrosis by secreting collagen. Vitamin C (ascorbic acid) is a cofactor of prolyl‐hydroxylases that modify newly synthesized collagen on the route for secretion. Unlike most animals, humans cannot synthesize ascorbic acid and its role in liver fibrosis remains unclear. Here, we determined the effect of ascorbic acid and prolyl‐hydroxylase inhibition on collagen production and secretion by human HSCs. Primary human HSCs (p‐hHSCs) and the human HSCscell line LX‐2 were treated with ascorbic acid, transforming growth factor‐beta (TGFβ) and/or the pan‐hydroxylase inhibitor dimethyloxalylglycine (DMOG). Expression of collagen‐I was analyzed by RT‐qPCR ( COL1A1 ), Western blotting, and immunofluorescence microscopy. Collagen secretion was determined in the medium by Western blotting for collagen‐I and by HPLC for hydroxyproline concentrations. Expression of solute carrier family 23 members 1 and 2 ( SLC23A1 / SLC23A 2), encoding sodium‐dependent vitamin C transporters 1 and 2 (SVCT1/SVCT2) was quantified in healthy and cirrhotic human tissue. In the absence of ascorbic acid, collagen‐I accumulated intracellularly in p‐hHSCs and LX‐2 cells, which was potentiated by TGFβ. Ascorbic acid co‐treatment strongly promoted collagen‐I excretion and enhanced extracellular hydroxyproline concentrations, without affecting collagen‐I ( COL1A1 ) mRNA levels. DMOG inhibited collagen‐I release even in the presence of ascorbic acid and suppressed COL1A1 and alpha‐smooth muscle actin (αSMA/ ACTA2 ) mRNA levels, also under hypoxic conditions. Hepatocytes express both ascorbic acid transporters, while p‐hHSCs and LX‐2 express the only SVCT2, which is selectively enhanced in cirrhotic livers. Human HSCs rely on ascorbic acid for the efficient secretion of collagen‐I, which can be effectively blocked by hydroxylase antagonists, revealing new therapeutic targets to treat liver fibrosis.

1 September 2019 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
SSShiva Shajari
Shiva Shajari
ASAli Saeed
Ali Saeed
Natalia Smith-CortinezNatalia Smith-Cortinez
Natalia Smith-Cortinez
JHJanette Heegsma
Janette Heegsma
SSSvenja Sydor
Svenja Sydor
KFKlaas Nico Faber
Klaas Nico Faber